Clinical trial · Interventional
High-Dose Melphalan With or Without Radiolabeled Monoclonal Antibody in Treating Patients With Multiple Myeloma Undergoing an Autologous Stem Cell Transplant
A Randomised Phase II Clinical Trial Using Targeted Radiotherapy Delivered by an Yttrium-90 Radio-Labelled Anti-CD66 Monoclonal Antibody With High Dose Melphalan Compared to Melphalan Alone, Prior to Autologous Stem Cell Transplantation for Multiple Myeloma
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Why stopped (as posted): Low recruitment
Summary
Brief summary (as posted)
RATIONALE: Drugs used in chemotherapy, such as melphalan, work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing. Radiolabeled monoclonal antibodies can find cancer cells and carry cancer-killing substances to them without harming normal cells. A stem cell transplant using stem cells from the patient may be able to replace blood-forming cells that were destroyed by the chemotherapy and radiolabeled monoclonal antibody. PURPOSE: This randomized phase II trial is studying how well high-dose melphalan works when given with or without radiolabeled monoclonal antibody in treating patients with multiple myeloma undergoing an autologous stem cell transplant.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Multiple Myeloma and Plasma Cell Neoplasm | — | UNRESOLVED | — |
Interventions
Interventions (3)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| autologous hematopoietic stem cell transplantation | Procedure | — | UNRESOLVED |
| melphalan | Drug | Melphalan | ALIAS |
| yttrium Y 90 anti-CD66 monoclonal antibody BW 250/183 | Radiation | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- type
- EXPERIMENTAL
- label
- radio-labelled anti-CD66 monoclonal antibody
- description
- Up to 4mg radio-labelled anti-CD66 monoclonal antibody. Plus standard treatment
- interventionNames
- Drug: melphalan
- Procedure: autologous hematopoietic stem cell transplantation
- Radiation: yttrium Y 90 anti-CD66 monoclonal antibody BW 250/183
- type
- ACTIVE_COMPARATOR
- label
- No IMP - standard treatment
- description
- No IMP - standard treatment
- interventionNames
- Drug: melphalan
- Procedure: autologous hematopoietic stem cell transplantation
Primary outcomes (1)
- measure
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
- Maximum age
- 120 Years
Show eligibility criteria text
DISEASE CHARACTERISTICS: * Histologically or cytologically proven multiple myeloma (MM) * Scheduled to undergo autologous hematopoietic stem cell transplantation (HSCT) as consolidation treatment for MM * Must have sufficient CD34-positive stem cells (≥ 4 x 10\^6 cells per kg body weight) in cryo-storage for two autologous HSCTs * In partial remission (PR) after prior chemotherapy but before priming therapy for stem cell mobilization * Patients in complete remission (CR) after prior chemotherapy are not eligible * Bone marrow cellularity ≥ 20% PATIENT CHARACTERISTICS: * WHO performance status 0-1 * Life expectancy ≥ 24 weeks * Hemoglobin ≥ 9.0 g/dL * Neutrophils ≥ 1,500/mm³ * Platelets ≥ 50,000/mm³ * Serum bilirubin ≤ 1.5 times upper limit of normal (ULN) * ALT and/or AST ≤ 2.5 times ULN * Creatinine clearance ≥ 50 mL/min * Not pregnant or nursing * Negative pregnancy test * Fertile female patients must use effective contraception for 4 weeks prior to, during, and for 6 months after completion of study treatment * Fertile male patients must use effective contraception during and for 6 months after completion of study treatment * Able to cooperate with study treatment and follow up * Human anti-mouse antibody (HAMA) negative * No active uncontrolled infection * No high-risk non-malignant systemic disease * No other condition, that in the investigator's opinion, would make the patient an unsuitable candidate for the study * No known HIV or hepatitis B or C seropositivity * No history of allergy, including an allergy to rodents or rodent proteins * No history of eczema or asthma * No history of New York Heart Association (NYHA) class III or IV cardiac disease * No congestive heart failure PRIOR CONCURRENT THERAPY: * Recovered from prior therapy * Alopecia or certain grade 1 toxicities allowed * More than 4 weeks since prior radiotherapy (except for localized pain control), endocrine therapy, or immunotherapy * More than 4 weeks since prior and no other concurrent chemotherapy for the underlying hematological condition, except for the following: * Cyclophosphamide as priming for stem cell harvest * Thalidomide * More than 3 weeks since prior major thoracic and/or abdominal surgery and recovered * No prior high-dose therapy and autologous HSCT * Concurrent radiotherapy allowed for the control of bone pain * The irradiated lesions are not used for response evaluation * No other concurrent anti-cancer therapy or investigational drugs during transplantation conditioning
References
Publications (0)
Data not yet available